Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Mind Medicine Inc (MMED.NE)

Mind Medicine Inc (MMED.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition FinancialNewsMedia - Wed Jan 24, 8:00AM CST

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CYBN.NE : 0.4700 (unch)
MMED.NE : 14.9000 (+9.48%)
CYBN : 0.3480 (-0.85%)
ATAI : 1.6800 (-2.89%)
MNMD : 8.29 (+2.09%)
SEEL : 1.5900 (-8.88%)
CMPS : 7.83 (-1.14%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031 FinancialNewsMedia - Wed Jul 26, 2023

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 0.4700 (unch)
MMED.NE : 14.9000 (+9.48%)
CYBN : 0.3480 (-0.85%)
CMPS : 7.83 (-1.14%)
SEEL : 1.5900 (-8.88%)
MNMD : 8.29 (+2.09%)
NUMIF : 0.0500 (-9.09%)
NUMI.TO : 0.0700 (unch)
MindMed Reports First Quarter 2023 Financial Results and Business Highlights Business Wire - Thu May 4, 2023

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 14.9000 (+9.48%)
MNMD : 8.29 (+2.09%)
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy Business Wire - Tue May 2, 2023

The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...

MMED.NE : 14.9000 (+9.48%)
MNMD : 8.29 (+2.09%)
INCY : 57.20 (+0.02%)
SGEN : 228.74 (-0.07%)
PFE : 28.47 (-0.21%)
FBRX : 0.6165 (+1.55%)
JAZZ : 106.99 (-1.50%)
ALC : 88.44 (+0.39%)
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update Business Wire - Mon May 1, 2023

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 14.9000 (+9.48%)
MNMD : 8.29 (+2.09%)
MindMed to Participate in May Investor Conferences Business Wire - Wed Apr 26, 2023

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 14.9000 (+9.48%)
MNMD : 8.29 (+2.09%)
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting Business Wire - Tue Apr 18, 2023

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 14.9000 (+9.48%)
MNMD : 8.29 (+2.09%)
INCY : 57.20 (+0.02%)
BMY : 42.47 (-2.05%)
SGEN : 228.74 (-0.07%)
FBRX : 0.6165 (+1.55%)
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD) Business Wire - Fri Apr 14, 2023

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced...

MMED.NE : 14.9000 (+9.48%)
MNMD : 8.29 (+2.09%)
MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary Business Wire - Thu Apr 13, 2023

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 14.9000 (+9.48%)
MNMD : 8.29 (+2.09%)
CARM : 1.4000 (-0.71%)
MODL : 36.37 (+0.11%)
MindMed Reports Full Year 2022 Financial Results and Business Highlights Business Wire - Thu Mar 9, 2023

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MMED.NE : 14.9000 (+9.48%)
MNMD : 8.29 (+2.09%)

Barchart Exclusives

Investing in Gold? Forget GLD, Buy PHYS Instead Barchart - 8 minutes ago
Many groups are piling into gold, including central banks and sovereign governments. Gold has also become very popular among individual Chinese investors and family offices that cater to the global rich. Most of these investors choose physical gold. That's what famed investor Michael Burry did. But instead of the GLD ETF, he opted for another physical gold ETF - PHYS. Find out why. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot